



PROGRAMME OVERVIEW

November 22, 2017

Pivot Park, Oss the Netherlands

update November 19, 2017

'BUILDING THE FUTURE'

07:30 **Registration desk open**

08:00 **CxO breakfast meeting:** for CEOs, CFOs, COOs and CBOs active in the life sciences sector

hosted by  **ABN-AMRO**

by **Yurry Hendriks**, Head of Blockchain & Smart Contracts Lab at ABN AMRO Bank N.V.

During this breakfast session Block Chain specialist **Yurry** Hendriks will provide an introduction to Block Chain technology and how companies using these next generation technologies that will impact the Life Sciences industry. Subsequently the participants will have the opportunity during the round table discussions to share knowledge, experiences and how your company could prepare for this new technology. Furthermore Block Chain experts will take questions over this continental breakfast session. Blockchain technology and the impact on the life sciences industry.

Limited places are available and only to MT members from (R&D) life sciences companies who are attending the conference.

09:00 **Exhibition and startup corner open**

09:45-09:50 **Welcome by chair**

Dr. Anne Bruinvels, Founder Px HealthCare

09:50-10:00 **Opening**

hosted by 

by **Mirjam Mol MD**, Director Pivot Park

10:00-10:30 **Keynote lecture:**

Mitochondrial drug development; from drawing board to medical applications.

by **Prof. dr. Jan Smeitink**, Professor in Mitochondrial Medicine, founding CEO Khondrion BV, member of the Academia Europaea

Mitochondrial diseases are a clinically heterogeneous group of disorders that arise as a result of dysfunction of the mitochondrial respiratory chain. Prof. dr. Jan Smeitink will give an overview on the current status in this emerging field including the known mitochondrial disorders and the drug development programmes. In addition he will address the strategy of his pharmaceutical company Khondrion to treat mitochondrial diseases with innovative drugs.

10:30-10:55 **Venture Challenge**

hosted by 

The winner of the Venture Challenge will be announced!

Presentation by **Dr.ir. Chrétien Herben**, Manager Valorisation at Health~Holland




10:55-11:30 **Break**

hosted by  **Informed Consulting**

Exhibition and startup corner open

11:30-12:45 **Parallel morning sessions**



<p>Investors forum part 1</p> <p>The Investors forum is an exciting opportunity for those companies looking for equity capital and/or partnerships with companies and institutes across the life sciences value chain, from biotech, med tech and pharma companies to financiers and universities. The forum offers excellent opportunities for presenting your company or university to all major Dutch life sciences investors and discuss your business strategy, technology direction and capital-raising plan.</p> <p>MODERATOR: Harrold van Barlingen, Managing Partner at Thuja Capital</p>	<p>Medical food: developments and opportunities</p> <p>The field of candidates for development into medical foods is expanding continuously due to advances in the understanding of nutrition and disease, coupled with developments in food technology increasing the number of products that can be formulated and commercialized. In this session the most recent innovations, trends and concerns as well as practical challenges encountered and solutions adopted in the fields of medical food are being discussed.</p> <p>MODERATOR: Rein Strijker, CEO VitalneXt BV</p>	<p>Early stage diagnostics and healthcare</p> <p>There exists a significant need for advancement in the field of diagnostics. From pharma companies wanting novel biomarkers to more accurately stratify patients for clinical trials, to the rise of personalized therapies via genomic testing, there's a growing need for more accurate diagnostics and in many disease areas.</p> <p>HOSTED BY </p> <p>MODERATOR: Mark Jolink, European & Dutch Patent Attorney at EP&C</p>
<p>PITCHING COMPANIES T.B.A.</p>	<p>SPEAKERS:</p> <ul style="list-style-type: none"> ▪ Rein Strijker, Chief Executive Officer VitalneXt BV ▪ Herman Ermens, Business Development Director, Managing Director Medical Nutrition FrieslandCampina ▪ Hans van der Saag, Managing Director BioActor 	<p>SPEAKERS:</p> <ul style="list-style-type: none"> ▪ Prof.dr Wiek van Gilst, scientific counsellor Dutch Heart Association ▪ Dharminder Chahal, CEO SkylineDx ▪ Dr. Jan Groen, President and CEO Executive Member of the Board MDxHealth

12:45-13:45 **Lunch**

Exhibition and startup corner open



13:45-15:00 **Parallel afternoon sessions**

<p>Investors forum part 2 The Investors forum is an exciting opportunity for those companies looking for equity capital and/or partnerships with companies and institutes across the life sciences value chain, from biotech, med tech and pharma companies to financiers and universities. The forum offers excellent opportunities for presenting your company or university to all major Dutch life sciences investors and discuss your business strategy, technology direction and capital-raising plan.</p> <p>MODERATOR: Harrold van Barlingen, Managing Partner Thuja Capital</p>	<p>Drug delivery The drug delivery landscape is rapidly evolving to accommodate new biopharmaceuticals and is now a highly competitive space. The market attracts both start-ups and major players in the medical device, pharmaceutical and biotechnology industries. In this session market developments, challenges and several drug delivery approaches will be discussed.</p> <p>HOSTED BY  pwc MODERATOR: Peter Paul Hoek, Director Pharma, Life Sciences & MedTech PwC</p>	<p>Electronic- and mobile healthcare: benefits for clinicians and patients The global market for E/M-healthcare is growing fast which is also confirmed by investments from players such as Apple, Google and Samsung. In this session three companies will present their E and M-health solutions and business strategies for the health challenges. Topics like market access, healthcare integration strategies and awareness among patients and healthcare practitioners will be addressed.</p> <p>HOSTED BY  AXON science based lawyers MODERATOR: mr. Erik Vollebregt, Partner Axon Lawyers</p>
<p>PITCHING COMPANIES T.B.A.</p>	<p>SPEAKERS:</p> <ul style="list-style-type: none"> ▪ Mike de Leeuw, CEO and Founder OncoLize ▪ Jan Gossen, CEO and Founder Osteo-Pharma BV ▪ Frans Lichtenauer, CEO mu-Drop 	<p>SPEAKERS:</p> <ul style="list-style-type: none"> ▪ Maarten den Braber, Founder Nexthealth ▪ Dr. Anne Bruinvels, Founder Px HealthCare ▪ Yosef Safi Harb, Founder Happitech
<p style="text-align: center;">Pivot Park Tour</p> <p style="text-align: center;">Visit two of the companies that are making Pivot Park the hotspot for pharmaceutical innovation. See how drug discovery is accelerated at the Pivot Park Screening Centre and learn about the manufacturing process of pharmaceutical ingredients and nanomedicines at ChemConnection.</p>		

15:00-15:45 **Break, networking** > Exhibition and startup corner open
hosted by  **Informed Consulting**

15:45-16:10 **Keynote lecture:**

by **Emiel Hendriksen**, Enterprise Sales Manager Benelux at Tesla Motors

Tesla Motor's success is a clear demonstration of the importance of innovation in business. The company progressed from a niche car manufacturer to the driving force behind advances in renewables, energy storage and sustainable technology. Emiel Hendriksen will talk about what Tesla has done that makes them disruptive in the automotive industry, their innovation strategy and business models they apply.



16:10-16:20 **Announcement winner investors forum**

16:20-16:35 **Interview**

with **Marisca Urbanus van den Honaard**, Patient Advocate - Inspire2Live.

16:35-17:05 **Final keynote lecture:**

by **Sebastian Nijman, PhD**, Co-founder and Managing Director at Scenic Biotech BV

Sebastian Nijman is co-founder of Scenic Biotech and Associate Professor of the Ludwig Institute for Cancer Research at Oxford University. He will talk about the new venture Scenic Biotech, an international collaboration from Oxford University and the Netherlands Cancer Institute (NKI). The therapeutics spinout company raised €6.5m in Series A financing, which will be used to develop its 'genetic off-switch' for cancer and rare genetic diseases.

17:05-17:20 **Wrap up and closing act**

17:20-18:45 **Reception**, Drinks, bites and networking > Exhibition and startup corner open
